Compare CDMOs with cell and gene therapy manufacturing capabilities for viral vectors, CAR-T processing, and advanced therapy production.
Cell and gene therapy manufacturing requires specialized capabilities distinct from conventional biologics. Cell therapy involves processing living cells (autologous from patients or allogeneic from donors) under GMP conditions. Gene therapy involves producing viral vectors (AAV, lentiviral, retroviral, adenoviral) that deliver genetic material to target cells.
Manufacturing scalability is the central challenge. Autologous cell therapies (patient-specific, like CAR-T) must be manufactured in individual lots with complex chain-of-custody logistics. Allogeneic therapies and viral vectors follow more traditional batch manufacturing but face scale-up difficulties unique to biological production systems.
No companies found in this category yet. Check back soon.
Browse all CDMOsOur AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.